As per reports, the U.S. Food and Drug Administration has approved AstraZeneca (AZN) and Amgen’s (AMGN) asthma drug, Tezspire, to treat severe asthma for those aged 12 years and above. The approval comes based on late-stage trial data that shows the drug cut the rate of asthma attacks by 56% among patients when compared with placebo. Amgen informed that it was working to make Tezspire available to patients in January. Tezspire works by blocking a type of immune protein called TSLP, found in the linings of the lungs.
AstraZeneca will record sales outside U.S and Amgen will record sales in the United States. Both will also draw collaboration revenue from the profits.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.